Zduniak Krzysztof, Agrawal Siddarth, Symonowicz Krzysztof, Jurczyszyn Kamil, Ziółkowski Piotr
Prof. dr Piotr Ziółkowski Department of Pathology Wroclaw Medical University 1 Marcinkowskiego 50-368 Wrocław, Poland tel. +48 71 784 12 12 fax +48 71 784 00 57 e-mail:
Pol J Pathol. 2014 Mar;65(1):48-54. doi: 10.5114/pjp.2014.42669.
Nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) is a chromosomal protein of unknown function. Its amino acid composition and structure of its DNA binding domain resemble those of high mobility group A (HMGA) proteins which are associated with various malignancies. Since changes in expression of HMGA are considered as a marker of tumor progression, it is possible that similar changes in expression of NUCKS could be a useful tool in diagnosis of malignant skin tumors. To investigate this assumption we used specific antibodies against NUCKS for immunohistochemistry of squamous (SCC) and basal cell carcinoma (BCC) as well as keratoacanthoma (KA). We found high expression of NUCKS in nuclei of SCC and BCC cells which exceeded expression of the well-known proliferation marker Ki67. Expression of NUCKS in benign KA was much below that of malignant tumors. With the present study and based on our previous experience we would like to suggest the NUCKS protein as a novel proliferation marker for immunohistochemical evaluation of formalin-fixed and paraffin-embedded skin tumor specimens. We would like to emphasize that NUCKS abundance in malignant skin tumors is higher than that of the well-known proliferation marker Ki67, thus allowing more precise assessment of tumor proliferation potential.
核普遍存在的酪蛋白和细胞周期蛋白依赖性激酶底物(NUCKS)是一种功能未知的染色体蛋白。其氨基酸组成和DNA结合结构域的结构类似于与各种恶性肿瘤相关的高迁移率族A(HMGA)蛋白。由于HMGA表达的变化被认为是肿瘤进展的标志物,因此NUCKS表达的类似变化可能成为恶性皮肤肿瘤诊断的有用工具。为了研究这一假设,我们使用针对NUCKS的特异性抗体对鳞状细胞癌(SCC)、基底细胞癌(BCC)以及角化棘皮瘤(KA)进行免疫组织化学检测。我们发现NUCKS在SCC和BCC细胞核中高表达,其表达水平超过了著名的增殖标志物Ki67。NUCKS在良性KA中的表达远低于恶性肿瘤。基于本研究及我们之前的经验,我们建议将NUCKS蛋白作为一种新型增殖标志物,用于福尔马林固定石蜡包埋皮肤肿瘤标本的免疫组织化学评估。我们要强调的是,恶性皮肤肿瘤中NUCKS的丰度高于著名的增殖标志物Ki67,从而能够更精确地评估肿瘤增殖潜能。